WASHINGTON, Oct 16 (Reuters) - Advisors to the U.S. Food and Drug Administration on Tuesday said a group of kidney disease drugs may be approved in a broader patient population, which could expand the market for the drugs.Advisors to the FDA voted 8-4 that the drugs, known as phosphate binders, may be useful for patients before they go on dialysis, FDA spokeswoman Sandy Walsh said. They are now used to treat end-stage kidney disease.
